Monitor therapy and identify disease recurrence in individuals with metastatic breast cancer. Do not use for diagnosis or screening of breast cancer.
Quantitative Electrochemiluminescent Immunoassay
This test is New York DOH approved.
The Roche CA 15-3 electrochemiluminescent immunoassay is used. Results obtained with different methods or kits cannot be used interchangeably. The CA 15-3 test is used to aid in the management of Stage II and III breast cancer patients. Serial testing for patient CA 15-3 values should be used in conjunction with other clinical methods for monitoring breast cancer. Patients with confirmed breast carcinoma frequently have CA 15-3 values in the same range as healthy individuals. Elevations may be observed in patients with nonmalignant disease. Therefore, a CA 15-3 value, regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease.